Anumana and Pfizer partner for cardiovascular disease detection
Related Articles
JACC Featured Science: ECG-AI For HF Risk; ANSWER-HF; NEO-MINDSET; MANIFEST-US
Featured science studies simultaneously published in JACC and presented at AHA 2025 looked at artificial intelligence applied to an electrocardiogram (ECG-AI) for heart failure (HF) risk, treatment of Chagas disease, early aspirin withdrawal in…November 10, 2025
Midwest providers eye new financial opportunities
Modern Healthcare: Mayo Clinic announced a new technology platform initiative to deliver the next generation of clinical decision support tools, diagnostic insights and care recommendations to help clinicians make faster…April 18, 2021
FDA Grants Breakthrough Device Designation to Anumana’s ECG Pulmonary Hypertension Early Detection AI Algorithm
DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Device Designation to itsAI-enhanced, ECG-basedPulmonary Hypertension(PH) Early…May 23, 2022
Cardiology’s AI Moment: Anumana’s Top Insights from ACC.25
#TeamAnumana wrapped up three incredible days of exploring cardiovascular science in the Windy City at the American College of Cardiology’s Annual Scientific Session. ACC.25 brought together thousands of cardiologists, investigators,…April 22, 2025